Sporos Bioventures, LLC, a Houston, TX-based company formed to catalyze the development of therapies that target novel disease mechanisms in cancer and immune diseases, closed a $38.1m Series A financing.
The company plans to use the proceeds to support the development of lead assets across its portfolio and build out the team.
Sporos identifies novel disease mechanisms and strategically deploys talent, capital and access to operational resources to catalyze the development of breakthrough medicines. Its current pipeline is diversified across four entities and includes multiple clinical-stage candidates that are being investigated for the treatment of multiple indications in cancer and immune disease.
Sporos Bioventures to develop therapies for cancer, immune diseases bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
point in our ability to really make cancer history. but it s going to be with us for a long time. we ll take it. thank you for all your hard work to you and your team. dr. ronald depinho, thank you. you re welcome. coming up next, a new twist in the case of steven avery, the focus of the making a murderer true crime now being accused of abuse by his ex fiancee. her exclusive interview with our sister network hln. . but what if you could wake up to lower blood sugar? imagine loving your numbers. discover once-daily invokana®. with over 6 million prescriptions and counting, it s the #1 prescribed sglt2 inhibitor that works to lower a1c. invokana® is used along with diet and exercise to significantly lower blood sugar in adults with type 2 diabetes. it s a once-daily pill that works around the clock.